Chronic Obstructive Pulmonary Disease | Decision Base | US | 2015
How Can Novel LABA/LAMA Combinations Differentiate Themselves in an Increasingly Crowded Market?
Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is commonplace as patients’ COPD worsens. Although substantial opportunity exists for a disease-modifying therapy, development of new COPD therapies has focused instead on therapies that combine two bronchodilators in one inhaler. As the COPD marketplace becomes increasingly crowded with these fixed-dose combinations, emerging therapies will need to be clearly differentiated from competitors to experience substantial uptake.
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
